Literature DB >> 7093099

A review of the haemodynamic effects of labetalol in man.

J N Cohn, J Mehta, G S Francis.   

Abstract

1 Labetalol at a dose of 800 to 1600 mg daily inhibited isoprenaline-induced tachycardia and phenylephrine-induced elevation in arterial pressure in hypertensive subjects. The beta-adrenoreceptor effect was four times more potent than the alpha-adrenoreceptor effect. 2 Isoprenaline-induced tachycardia was more effectively blocked than isoprenaline-induced inotropism, thereby raising the possibility of a subselective effect on cardiac beta-adrenoceptors. 3 Labetalol reduced blood pressure in hypertensive subjects with no change in cardiac output in the supine or upright position and with marked inhibition of the heart rate and blood pressure response to treadmill exercise. 4 Labetalol administered in single doses to patients with stable, treated congestive heart failure impaired blood pressure support during exercise. 5 The unique adrenoceptor and haemodynamic effects of labetalol make it a potentially attractive drug for management of hypertension and other cardiovascular disorders.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7093099      PMCID: PMC1401835          DOI: 10.1111/j.1365-2125.1982.tb01885.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Circulatory and alpha-adrenoceptor blocking effects of phentolamine.

Authors:  D A Richards; E P Woodings; B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1978-06       Impact factor: 4.335

2.  Alpha and beta blockers: effects on renin release.

Authors:  R H McDonald; C N Corder; F H Leenen
Journal:  Prog Brain Res       Date:  1977       Impact factor: 2.453

3.  Mechanism of exercise hypotension after sympathetic blockade.

Authors:  I M Khatri; J N Cohn
Journal:  Am J Cardiol       Date:  1970-03       Impact factor: 2.778

4.  Effects of beta-adrenergic blockade on the cardiac response to maximal and submaximal exercise in man.

Authors:  S Epstein; B F Robinson; R L Kahler; E Braunwald
Journal:  J Clin Invest       Date:  1965-11       Impact factor: 14.808

5.  Prazosin: the first-dose phenomenon.

Authors:  R M Graham; I R Thornell; J M Gain; C Bagnoli; H F Oates; G S Stokes
Journal:  Br Med J       Date:  1976-11-27

Review 6.  Vasodilator therapy of cardiac failure: (first of two parts).

Authors:  J N Cohn; J A Franciosa
Journal:  N Engl J Med       Date:  1977-07-07       Impact factor: 91.245

7.  Evidence for an intrarenal beta receptor in control of renin release.

Authors:  J A Johnson; J O Davis; R W Gotshall; T E Lohmeier; J L Davis; B Braverman; G E Tempel
Journal:  Am J Physiol       Date:  1976-02

8.  Hemodynamic changes after beta adrenergic blockade.

Authors:  E Sowton; J Hamer
Journal:  Am J Cardiol       Date:  1966-09       Impact factor: 2.778

9.  Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects.

Authors:  J Mehta; J N Cohn
Journal:  Circulation       Date:  1977-02       Impact factor: 29.690

10.  Hemodynamic effect of dobutamine in patients with severe heart failure.

Authors:  N Akhtar; E Mikulic; J N Cohn; M H Chaudhry
Journal:  Am J Cardiol       Date:  1975-08       Impact factor: 2.778

View more
  5 in total

1.  Labetalol: the nineteen-eighties.

Authors:  J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 2.  Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.

Authors:  P Lund-Johansen
Journal:  Drugs       Date:  1984       Impact factor: 9.546

Review 3.  Pharmacology of combined alpha-beta-blockade. I.

Authors:  W J Louis; J J McNeil; O H Drummer
Journal:  Drugs       Date:  1984       Impact factor: 9.546

4.  Proof of concept of a 45-second cardiorespiratory fitness self-test for coronary artery disease patients based on accelerometry.

Authors:  Gabriele Papini; Alberto G Bonomi; Wim Stut; Jos J Kraal; Hareld M C Kemps; Francesco Sartor
Journal:  PLoS One       Date:  2017-09-06       Impact factor: 3.240

Review 5.  Current and Emerging Classes of Pharmacological Agents for the Management of Hypertension.

Authors:  Utkarsh Ojha; Sanjay Ruddaraju; Navukkarasu Sabapathy; Varun Ravindran; Pitchaya Worapongsatitaya; Jeesanul Haq; Raihan Mohammed; Vinod Patel
Journal:  Am J Cardiovasc Drugs       Date:  2021-12-08       Impact factor: 3.283

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.